Ossium Health Trials Off-the-Shelf Bone Marrow From Deceased Donors to Help Save More Lives
Ossium Health, an innovative bioengineering company, is accelerating its mission to revolutionize the field of bone marrow transplantation through a new partnership with the National Marrow Donor Program (NMDP)/Be The Match, which manages the most diverse registry of blood stem cell donors and cord blood units in the world. This collaboration will enable blood cancer patients to access transplantable units of bone marrow from deceased donors through clinical trials, providing a much-needed complement to today’s living donor model.
Kevin Caldwell, CEO & Co-Founder at Ossium Health, said, “As Ossium continues on this journey to transform bone marrow transplantation, our partnership with NMDP/Be The Match becomes a beacon of hope for the tens of thousands of patients seeking a bone marrow transplant annually. Together, we’re resolute in our commitment to turning life-saving matches into a universal reality.”
With more than 18,000 US blood cancer patients in desperate need of a bone marrow transplant each year, the urgency for a more accessible and efficient transplantation process has never been higher. NMDP/Be The Match successfully matches over 7,000 patients per year with volunteer donors and has facilitated more than 125,000 transplants since its establishment in 1987.
While NMDP/Be The Match has enabled considerable increases in unrelated donor transplants performed, an unmet need still exists. Many patients never receive a transplant due to disease progression or relapse during the donor identification process. Overall, up to 45% of those seeking a transplant find themselves unable to receive one in time. Together, NMDP/Be The Match and Ossium are taking new strides to address this critical healthcare challenge.
To improve access to bone marrow transplants, Ossium has developed off-the-shelf, cryopreserved bone marrow (Ossium, HPC Marrow) that can slash transplant wait times and enable life-saving stem cell transplants for patients who need them most. The company is expanding the gift of organ donation and potentially increasing the number of lives saved through a previously unused source of bone marrow: vertebral bones from organ donors. These ready-to-use bone marrow units can be rapidly deployed to patients who need a transplant.
The need for alternative graft sources came to light during the COVID-19 pandemic, which strained the living donor system. New logistical hurdles during this period led bone marrow donor registries around the globe to temporarily mandate cryopreservation of bone marrow from live donors, significantly improving transplant logistics and aligning closely with Ossium’s process.
The stress that the pandemic placed on global supply chains demonstrated the value and resilience of ready-to-use medical products and highlighted the importance of diversifying graft sources to ensure uninterrupted patient access to bone marrow transplantation. Ossium’s major innovation in donor sourcing combined with well-established cryopreservation technology has set the stage for its transformative off-the-shelf bone marrow bank.
Now, following a successful $52 million Series C funding round that brought total capital raised to over $120 million since the company’s founding in 2016, Ossium is taking another bold step forward by partnering with NMDP/Be The Match. As part of this collaboration, Ossium and the NMDP/Be The Match are conducting clinical trials through CIBMTR® (Center for International Blood and Marrow Transplant Research(R)) to define the safety and efficacy of Ossium, HPC Marrow.
Ossium Health’s pioneering approach not only brings hope to patients but also has the potential to impact the field of bone marrow transplantation. By addressing existing shortages and logistical challenges, and by expanding and enhancing current registries with an on-demand bone marrow product with optimal cell dose, Ossium is pioneering a novel approach to bone marrow transplantation.
The National Marrow Donor Program® (NMDP)/Be The Match® is the leading global partner working to save lives through cellular therapy. With 35 years of experience managing the most diverse registry of potential unrelated blood stem cell donors and cord blood units in the world, NMDP/Be The Match is a proven partner in providing cures to patients with life-threatening blood and marrow cancers and diseases. Through their global network, they connect centers and patients to their best cell therapy option—from blood stem cell transplant to a next-generation therapy—and collaborate with cell and gene therapy companies to support therapy development and delivery through Be The Match BioTherapies®. NMDP/Be The Match is a tireless advocate for the cell therapy community, working with hematologists/oncologists to remove barriers to consultation and treatment, and supporting patients through no-cost programs to eliminate non-medical obstacles to cell therapy. In addition, they are a global leader in research through the CIBMTR® (Center for International Blood and Marrow Transplant Research®)—a collaboration with the Medical College of Wisconsin, investing in and managing research studies that improve patient outcomes and advance the future of care.
Center for International Blood and Marrow Transplant Research® (CIBMTR) is a nonprofit research collaboration between the National Marrow Donor Program (NMDP)/Be The Match, in Minneapolis, and the Medical College of Wisconsin, in Milwaukee. CIBMTR collaborates with the global scientific community to increase survival and enrich quality of life for patients. CIBMTR facilitates critical observational and interventional research through scientific and statistical expertise, a large network of centers, and a unique database of long-term clinical data for more than 630,000 people who have received hematopoietic cell transplantation and other cellular therapies. Learn more at cibmtr.org.
Organization: Ossium Health
Contact Person: Kevin Caldwell
Email: [email protected]
City: San Francisco
Country: United States
Release Id: 3008235960